MGNX MacroGenics Inc.

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, March 15, 2023, at 4:30 pm ET.

Conference Call Information

To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at . A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

About MacroGenics, Inc.

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at . MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###



CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,   
EN
07/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MacroGenics Inc.

 PRESS RELEASE

MacroGenics Provides Update on Corporate Progress and First Quarter 20...

MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipelineMultiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC)Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nine monthsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-base...

 PRESS RELEASE

MacroGenics Announces Date of First Quarter 2023 Financial Results Con...

MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 9, 2023, at 4:3...

 PRESS RELEASE

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences: Stifel 2023 Targeted Oncology Days (Virtual). Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in a formal presentation on Wednesday, April 26, 2023, at 2:00 pm ET. MacroG...

 PRESS RELEASE

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of...

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr) ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration’s (FDA) approval of Incyte’s Biologics License Application (BLA) for ZYNYZ™ (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte. ZYNYZ, a humanized monoclonal antibody ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch